These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 33475294)

  • 1. Immunotherapy in Triple-Negative Breast Cancer.
    Emens LA
    Cancer J; 2021 Jan-Feb 01; 27(1):59-66. PubMed ID: 33475294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
    Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
    Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy Approaches for Breast Cancer Patients in 2023.
    Emens LA; Loi S
    Cold Spring Harb Perspect Med; 2023 Apr; 13(4):. PubMed ID: 37011999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.
    Heeke AL; Tan AR
    Cancer Metastasis Rev; 2021 Jun; 40(2):537-547. PubMed ID: 34101053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
    N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
    Kang C; Syed YY
    Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.
    Haiderali A; Huang M; Pan W; Akers KG; Maciel D; Frederickson AM
    Future Oncol; 2024; 20(22):1587-1600. PubMed ID: 38597713
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
    Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges.
    de Melo Gagliato D; Buzaid AC; Perez-Garcia J; Cortes J
    BioDrugs; 2020 Oct; 34(5):611-623. PubMed ID: 32870473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
    Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J
    Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Li CH; Karantza V; Aktan G; Lala M
    Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
    Cortés J; André F; Gonçalves A; Kümmel S; Martín M; Schmid P; Schuetz F; Swain SM; Easton V; Pollex E; Deurloo R; Dent R
    Future Oncol; 2019 Jun; 15(17):1951-1961. PubMed ID: 30977385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130).
    Iwata H; Inoue K; Kaneko K; Ito Y; Tsugawa K; Hasegawa A; Nakagawa S; Kuratomi H; Tamura K
    Jpn J Clin Oncol; 2019 Dec; 49(12):1083-1091. PubMed ID: 31612909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials of immunotherapy in triple-negative breast cancer.
    Howard FM; Pearson AT; Nanda R
    Breast Cancer Res Treat; 2022 Aug; 195(1):1-15. PubMed ID: 35834065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
    Cortes J; Haiderali A; Huang M; Pan W; Schmid P; Akers KG; Park JE; Frederickson AM; Fasching PA; O'Shaughnessy J
    BMC Cancer; 2023 Aug; 23(1):792. PubMed ID: 37612624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab and atezolizumab in triple-negative breast cancer.
    Kwapisz D
    Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
    Blackley EF; Loi S
    Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.